Boston Scientific Other decreased by 18.8% to $379.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 34.4%, from $282.00M to $379.00M. Over 4 years (FY 2020 to FY 2024), Other shows relatively stable performance with a 0.5% CAGR.
other_other_sundry_liabilities_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $268.00M | $255.00M | $228.00M | $241.00M | $193.00M | $220.00M | $230.00M | $217.00M | $242.00M | $234.00M | $278.00M | $246.00M | $222.00M | $282.00M | $313.00M | $302.00M | $467.00M | $379.00M |
| QoQ Change | — | -4.9% | -10.6% | +5.7% | -19.9% | +14.0% | +4.5% | -5.7% | +11.5% | -3.3% | +18.8% | -11.5% | -9.8% | +27.0% | +11.0% | -3.5% | +54.6% | -18.8% |
| YoY Change | — | — | — | — | -28.0% | -13.7% | +0.9% | -10.0% | +25.4% | +6.4% | +20.9% | +13.4% | -8.3% | +20.5% | +12.6% | +22.8% | +110.4% | +34.4% |